CN106399346A - 周期型马来丝虫m29表位基因蛋白疫苗的用途 - Google Patents
周期型马来丝虫m29表位基因蛋白疫苗的用途 Download PDFInfo
- Publication number
- CN106399346A CN106399346A CN201610826363.XA CN201610826363A CN106399346A CN 106399346 A CN106399346 A CN 106399346A CN 201610826363 A CN201610826363 A CN 201610826363A CN 106399346 A CN106399346 A CN 106399346A
- Authority
- CN
- China
- Prior art keywords
- myosin
- buffer
- pcr
- preparation
- 12000rpm
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 79
- 102000004169 proteins and genes Human genes 0.000 title claims abstract description 33
- 230000000737 periodic effect Effects 0.000 title claims abstract description 24
- 229940023143 protein vaccine Drugs 0.000 title claims abstract description 21
- 241000244038 Brugia malayi Species 0.000 title abstract 3
- 238000006243 chemical reaction Methods 0.000 claims abstract description 49
- 238000002360 preparation method Methods 0.000 claims abstract description 44
- 239000012634 fragment Substances 0.000 claims abstract description 26
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 claims abstract description 16
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 claims abstract description 16
- 239000013604 expression vector Substances 0.000 claims abstract description 9
- 238000010276 construction Methods 0.000 claims abstract description 8
- 230000014509 gene expression Effects 0.000 claims abstract description 7
- 230000009465 prokaryotic expression Effects 0.000 claims abstract description 7
- 238000012216 screening Methods 0.000 claims abstract description 7
- 230000010148 water-pollination Effects 0.000 claims abstract description 5
- 239000013598 vector Substances 0.000 claims abstract description 4
- 239000007788 liquid Substances 0.000 claims description 67
- 241000894006 Bacteria Species 0.000 claims description 56
- 239000000243 solution Substances 0.000 claims description 56
- 108060008487 Myosin Proteins 0.000 claims description 54
- 102000003505 Myosin Human genes 0.000 claims description 44
- 239000013612 plasmid Substances 0.000 claims description 43
- 239000000872 buffer Substances 0.000 claims description 39
- 239000000499 gel Substances 0.000 claims description 39
- 210000004027 cell Anatomy 0.000 claims description 38
- 239000006228 supernatant Substances 0.000 claims description 31
- 241000244036 Brugia Species 0.000 claims description 21
- 239000000203 mixture Substances 0.000 claims description 21
- 239000003292 glue Substances 0.000 claims description 20
- 239000001963 growth medium Substances 0.000 claims description 20
- 239000000706 filtrate Substances 0.000 claims description 18
- 238000011534 incubation Methods 0.000 claims description 18
- 210000002966 serum Anatomy 0.000 claims description 18
- 241000588724 Escherichia coli Species 0.000 claims description 17
- 238000005119 centrifugation Methods 0.000 claims description 16
- 238000000246 agarose gel electrophoresis Methods 0.000 claims description 15
- 239000002609 medium Substances 0.000 claims description 15
- 108091008146 restriction endonucleases Proteins 0.000 claims description 15
- 108091007433 antigens Proteins 0.000 claims description 14
- 239000000427 antigen Substances 0.000 claims description 13
- 102000036639 antigens Human genes 0.000 claims description 13
- 230000029087 digestion Effects 0.000 claims description 13
- 238000012360 testing method Methods 0.000 claims description 13
- 108010039343 HLA-DRB1 Chains Proteins 0.000 claims description 12
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 claims description 12
- 239000001110 calcium chloride Substances 0.000 claims description 12
- 229910001628 calcium chloride Inorganic materials 0.000 claims description 12
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 12
- 239000000047 product Substances 0.000 claims description 12
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 claims description 11
- 235000011148 calcium chloride Nutrition 0.000 claims description 11
- 238000012163 sequencing technique Methods 0.000 claims description 11
- 239000012154 double-distilled water Substances 0.000 claims description 10
- 102000008949 Histocompatibility Antigens Class I Human genes 0.000 claims description 9
- 108010088652 Histocompatibility Antigens Class I Proteins 0.000 claims description 9
- 230000001580 bacterial effect Effects 0.000 claims description 9
- 238000004140 cleaning Methods 0.000 claims description 9
- 239000003480 eluent Substances 0.000 claims description 9
- 230000002068 genetic effect Effects 0.000 claims description 9
- 238000000034 method Methods 0.000 claims description 9
- 238000011144 upstream manufacturing Methods 0.000 claims description 9
- 229920001817 Agar Polymers 0.000 claims description 8
- 239000008272 agar Substances 0.000 claims description 8
- 230000004087 circulation Effects 0.000 claims description 8
- 239000000284 extract Substances 0.000 claims description 8
- 230000006698 induction Effects 0.000 claims description 8
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 claims description 8
- 238000002156 mixing Methods 0.000 claims description 8
- 235000015097 nutrients Nutrition 0.000 claims description 8
- 229920000936 Agarose Polymers 0.000 claims description 7
- 238000012408 PCR amplification Methods 0.000 claims description 7
- 101000702488 Rattus norvegicus High affinity cationic amino acid transporter 1 Proteins 0.000 claims description 7
- 210000003719 b-lymphocyte Anatomy 0.000 claims description 7
- 230000027455 binding Effects 0.000 claims description 7
- FRXSZNDVFUDTIR-UHFFFAOYSA-N 6-methoxy-1,2,3,4-tetrahydroquinoline Chemical compound N1CCCC2=CC(OC)=CC=C21 FRXSZNDVFUDTIR-UHFFFAOYSA-N 0.000 claims description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 6
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 claims description 6
- 230000003321 amplification Effects 0.000 claims description 6
- 238000001816 cooling Methods 0.000 claims description 6
- 238000013461 design Methods 0.000 claims description 6
- 239000012530 fluid Substances 0.000 claims description 6
- 239000006166 lysate Substances 0.000 claims description 6
- 239000013642 negative control Substances 0.000 claims description 6
- 229910052759 nickel Inorganic materials 0.000 claims description 6
- 238000003199 nucleic acid amplification method Methods 0.000 claims description 6
- 230000035939 shock Effects 0.000 claims description 6
- 238000012546 transfer Methods 0.000 claims description 6
- 108091005804 Peptidases Proteins 0.000 claims description 5
- 239000004365 Protease Substances 0.000 claims description 5
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims description 5
- 239000007853 buffer solution Substances 0.000 claims description 5
- 238000012856 packing Methods 0.000 claims description 5
- 230000009514 concussion Effects 0.000 claims description 4
- LRBQNJMCXXYXIU-PPKXGCFTSA-N Chinese gallotannin Chemical compound OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-PPKXGCFTSA-N 0.000 claims description 3
- 102000012410 DNA Ligases Human genes 0.000 claims description 3
- 108010061982 DNA Ligases Proteins 0.000 claims description 3
- 108010005054 Deoxyribonuclease BamHI Proteins 0.000 claims description 3
- -1 HLA DRB1*0901 Proteins 0.000 claims description 3
- 108010047214 HLA-DRB1*03:01 antigen Proteins 0.000 claims description 3
- 108010029657 HLA-DRB1*04:01 antigen Proteins 0.000 claims description 3
- 108010066546 HLA-DRB1*08:01 antigen Proteins 0.000 claims description 3
- 102210010945 HLA-DRB1*0901 Human genes 0.000 claims description 3
- 102210005807 HLA-DRB1*1301 Human genes 0.000 claims description 3
- 239000006142 Luria-Bertani Agar Substances 0.000 claims description 3
- 208000006735 Periostitis Diseases 0.000 claims description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 3
- 108020005038 Terminator Codon Proteins 0.000 claims description 3
- 239000002585 base Substances 0.000 claims description 3
- 230000003115 biocidal effect Effects 0.000 claims description 3
- 230000002308 calcification Effects 0.000 claims description 3
- 230000001413 cellular effect Effects 0.000 claims description 3
- 238000005352 clarification Methods 0.000 claims description 3
- 239000002299 complementary DNA Substances 0.000 claims description 3
- 108091036078 conserved sequence Proteins 0.000 claims description 3
- 238000005859 coupling reaction Methods 0.000 claims description 3
- 239000012149 elution buffer Substances 0.000 claims description 3
- 230000001815 facial effect Effects 0.000 claims description 3
- 235000011187 glycerol Nutrition 0.000 claims description 3
- 238000010438 heat treatment Methods 0.000 claims description 3
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical class O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 claims description 3
- 229930027917 kanamycin Natural products 0.000 claims description 3
- 229910001629 magnesium chloride Inorganic materials 0.000 claims description 3
- 239000000155 melt Substances 0.000 claims description 3
- 230000009149 molecular binding Effects 0.000 claims description 3
- 239000002773 nucleotide Substances 0.000 claims description 3
- 125000003729 nucleotide group Chemical group 0.000 claims description 3
- 210000003460 periosteum Anatomy 0.000 claims description 3
- 239000013641 positive control Substances 0.000 claims description 3
- 238000001742 protein purification Methods 0.000 claims description 3
- 238000011084 recovery Methods 0.000 claims description 3
- 241000894007 species Species 0.000 claims description 3
- 239000000725 suspension Substances 0.000 claims description 3
- 210000001519 tissue Anatomy 0.000 claims description 3
- 230000009466 transformation Effects 0.000 claims description 3
- 239000003513 alkali Substances 0.000 claims description 2
- 108010006785 Taq Polymerase Proteins 0.000 claims 1
- 238000012549 training Methods 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 5
- 210000001744 T-lymphocyte Anatomy 0.000 abstract description 2
- 238000003752 polymerase chain reaction Methods 0.000 abstract 2
- 238000000746 purification Methods 0.000 abstract 2
- 230000004544 DNA amplification Effects 0.000 abstract 1
- 238000010367 cloning Methods 0.000 abstract 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 30
- 238000000926 separation method Methods 0.000 description 17
- 229940046168 CpG oligodeoxynucleotide Drugs 0.000 description 14
- 238000002347 injection Methods 0.000 description 14
- 239000007924 injection Substances 0.000 description 14
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 12
- 230000036039 immunity Effects 0.000 description 12
- 238000001514 detection method Methods 0.000 description 10
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 8
- 229910052802 copper Inorganic materials 0.000 description 8
- 239000010949 copper Substances 0.000 description 8
- 239000011521 glass Substances 0.000 description 8
- 238000001962 electrophoresis Methods 0.000 description 7
- 210000004698 lymphocyte Anatomy 0.000 description 7
- 239000012141 concentrate Substances 0.000 description 6
- UQLDLKMNUJERMK-UHFFFAOYSA-L di(octadecanoyloxy)lead Chemical compound [Pb+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O UQLDLKMNUJERMK-UHFFFAOYSA-L 0.000 description 6
- 238000010790 dilution Methods 0.000 description 6
- 239000012895 dilution Substances 0.000 description 6
- 210000000952 spleen Anatomy 0.000 description 6
- 238000002965 ELISA Methods 0.000 description 5
- 201000006353 Filariasis Diseases 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 5
- 239000006285 cell suspension Substances 0.000 description 5
- 238000011081 inoculation Methods 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- KWYHDKDOAIKMQN-UHFFFAOYSA-N N,N,N',N'-tetramethylethylenediamine Chemical compound CN(C)CCN(C)C KWYHDKDOAIKMQN-UHFFFAOYSA-N 0.000 description 4
- 210000001015 abdomen Anatomy 0.000 description 4
- 238000011088 calibration curve Methods 0.000 description 4
- NKLPQNGYXWVELD-UHFFFAOYSA-M coomassie brilliant blue Chemical compound [Na+].C1=CC(OCC)=CC=C1NC1=CC=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C=CC(=CC=2)N(CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=C1 NKLPQNGYXWVELD-UHFFFAOYSA-M 0.000 description 4
- 238000007865 diluting Methods 0.000 description 4
- 239000003085 diluting agent Substances 0.000 description 4
- 230000028993 immune response Effects 0.000 description 4
- 238000011068 loading method Methods 0.000 description 4
- 229940046166 oligodeoxynucleotide Drugs 0.000 description 4
- 238000010186 staining Methods 0.000 description 4
- 229960005486 vaccine Drugs 0.000 description 4
- 241000239183 Filaria Species 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 239000012228 culture supernatant Substances 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 239000002504 physiological saline solution Substances 0.000 description 3
- 229940126583 recombinant protein vaccine Drugs 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 230000005924 vaccine-induced immune response Effects 0.000 description 3
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 2
- 238000011238 DNA vaccination Methods 0.000 description 2
- 238000008157 ELISA kit Methods 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 101710163270 Nuclease Proteins 0.000 description 2
- 238000003639 Student–Newman–Keuls (SNK) method Methods 0.000 description 2
- RYYWUUFWQRZTIU-UHFFFAOYSA-N Thiophosphoric acid Chemical group OP(O)(S)=O RYYWUUFWQRZTIU-UHFFFAOYSA-N 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- UDSAIICHUKSCKT-UHFFFAOYSA-N bromophenol blue Chemical compound C1=C(Br)C(O)=C(Br)C=C1C1(C=2C=C(Br)C(O)=C(Br)C=2)C2=CC=CC=C2S(=O)(=O)O1 UDSAIICHUKSCKT-UHFFFAOYSA-N 0.000 description 2
- 230000003139 buffering effect Effects 0.000 description 2
- 210000005252 bulbus oculi Anatomy 0.000 description 2
- 229960003150 bupivacaine Drugs 0.000 description 2
- 229960001050 bupivacaine hydrochloride Drugs 0.000 description 2
- SIEYLFHKZGLBNX-UHFFFAOYSA-N bupivacaine hydrochloride (anhydrous) Chemical compound [Cl-].CCCC[NH+]1CCCCC1C(=O)NC1=C(C)C=CC=C1C SIEYLFHKZGLBNX-UHFFFAOYSA-N 0.000 description 2
- 210000004899 c-terminal region Anatomy 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 230000007969 cellular immunity Effects 0.000 description 2
- 230000001010 compromised effect Effects 0.000 description 2
- 210000002808 connective tissue Anatomy 0.000 description 2
- 238000005520 cutting process Methods 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000011049 filling Methods 0.000 description 2
- 238000001502 gel electrophoresis Methods 0.000 description 2
- RQFCJASXJCIDSX-UUOKFMHZSA-N guanosine 5'-monophosphate Chemical compound C1=2NC(N)=NC(=O)C=2N=CN1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O RQFCJASXJCIDSX-UUOKFMHZSA-N 0.000 description 2
- 235000013928 guanylic acid Nutrition 0.000 description 2
- 239000004226 guanylic acid Substances 0.000 description 2
- 230000004727 humoral immunity Effects 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 238000002649 immunization Methods 0.000 description 2
- 239000000568 immunological adjuvant Substances 0.000 description 2
- 230000031700 light absorption Effects 0.000 description 2
- 238000012417 linear regression Methods 0.000 description 2
- 210000002751 lymph Anatomy 0.000 description 2
- VQWNELVFHZRFIB-UHFFFAOYSA-N odn 1826 Chemical compound O=C1NC(=O)C(C)=CN1C(O1)CC(O)C1COP(O)(=O)OC1CC(N2C(NC(=O)C(C)=C2)=O)OC1COP(O)(=O)OC1CC(N2C3=C(C(NC(N)=N3)=O)N=C2)OC1COP(O)(=O)OC1CC(N2C(N=C(N)C=C2)=O)OC1COP(O)(=O)OC1CC(N2C3=NC=NC(N)=C3N=C2)OC1COP(O)(=O)OC1CC(N2C3=C(C(NC(N)=N3)=O)N=C2)OC1COP(O)(=O)OC1CC(N2C(NC(=O)C(C)=C2)=O)OC1COP(O)(=O)OC1CC(N2C(N=C(N)C=C2)=O)OC1COP(O)(=O)OC1CC(N2C(N=C(N)C=C2)=O)OC1COP(O)(=O)OC1CC(N2C(NC(=O)C(C)=C2)=O)OC1COP(O)(=O)OC(C(O1)COP(O)(=O)OC2C(OC(C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=O)OC2C(OC(C2)N2C(N=C(N)C=C2)=O)COP(O)(=O)OC2C(OC(C2)N2C3=NC=NC(N)=C3N=C2)COP(O)(=O)OC2C(OC(C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=O)OC2C(OC(C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=O)OC2C(OC(C2)N2C3=NC=NC(N)=C3N=C2)COP(O)(=O)OC2C(OC(C2)N2C(N=C(N)C=C2)=O)COP(O)(=O)OC2C(OC(C2)N2C(N=C(N)C=C2)=O)COP(O)(=O)OC2C(OC(C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(O)=O)CC1N1C=C(C)C(=O)NC1=O VQWNELVFHZRFIB-UHFFFAOYSA-N 0.000 description 2
- 244000045947 parasite Species 0.000 description 2
- 230000010412 perfusion Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- JCQBWMAWTUBARI-UHFFFAOYSA-N tert-butyl 3-ethenylpiperidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCCC(C=C)C1 JCQBWMAWTUBARI-UHFFFAOYSA-N 0.000 description 2
- 239000002699 waste material Substances 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 102000002585 Contractile Proteins Human genes 0.000 description 1
- 108010068426 Contractile Proteins Proteins 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 101100175482 Glycine max CG-3 gene Proteins 0.000 description 1
- 108010042653 IgA receptor Proteins 0.000 description 1
- 241001197446 Mus cypriacus Species 0.000 description 1
- 102100034014 Prolyl 3-hydroxylase 3 Human genes 0.000 description 1
- 241000244002 Wuchereria Species 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 125000003275 alpha amino acid group Chemical group 0.000 description 1
- 230000001001 anti-filiarial effect Effects 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 238000013528 artificial neural network Methods 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 125000003636 chemical group Chemical group 0.000 description 1
- 238000002485 combustion reaction Methods 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000003664 filaricide agent Substances 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000000422 nocturnal effect Effects 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
- C07K14/43536—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from worms
- C07K14/4354—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from worms from nematodes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/70—Vectors or expression systems specially adapted for E. coli
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0003—Invertebrate antigens
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/66—General methods for inserting a gene into a vector to form a recombinant vector using cleavage and ligation; Use of non-functional linkers or adaptors, e.g. linkers containing the sequence for a restriction endonuclease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Mycology (AREA)
- Immunology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Description
Claims (4)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610826363.XA CN106399346B (zh) | 2014-11-05 | 2014-11-05 | 周期型马来丝虫m29表位基因蛋白疫苗的用途 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610826363.XA CN106399346B (zh) | 2014-11-05 | 2014-11-05 | 周期型马来丝虫m29表位基因蛋白疫苗的用途 |
CN201410617874.1A CN104399069B (zh) | 2014-11-05 | 周期型马来丝虫m29表位基因蛋白疫苗的制备方法 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201410617874.1A Division CN104399069B (zh) | 2014-11-05 | 2014-11-05 | 周期型马来丝虫m29表位基因蛋白疫苗的制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN106399346A true CN106399346A (zh) | 2017-02-15 |
CN106399346B CN106399346B (zh) | 2019-10-18 |
Family
ID=52636778
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201610826365.9A Expired - Fee Related CN106344914B (zh) | 2014-11-05 | 2014-11-05 | 简便的周期型马来丝虫m29表位基因蛋白疫苗制备方法 |
CN201610824574.XA Expired - Fee Related CN106399345B (zh) | 2014-11-05 | 2014-11-05 | 一种周期型马来丝虫m29表位基因蛋白疫苗制备方法 |
CN201610826363.XA Active CN106399346B (zh) | 2014-11-05 | 2014-11-05 | 周期型马来丝虫m29表位基因蛋白疫苗的用途 |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201610826365.9A Expired - Fee Related CN106344914B (zh) | 2014-11-05 | 2014-11-05 | 简便的周期型马来丝虫m29表位基因蛋白疫苗制备方法 |
CN201610824574.XA Expired - Fee Related CN106399345B (zh) | 2014-11-05 | 2014-11-05 | 一种周期型马来丝虫m29表位基因蛋白疫苗制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (3) | CN106344914B (zh) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108106894B (zh) * | 2017-12-17 | 2020-09-08 | 吉林大学 | 昆虫细胞表达sST2做为测定血清中sST2浓度的校准品 |
CN108333134A (zh) * | 2018-02-05 | 2018-07-27 | 西北农林科技大学 | 便携式牛奶蛋白质含量快速检测方法和装置 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101624422A (zh) * | 2008-07-09 | 2010-01-13 | 中国农业科学院上海兽医研究所 | 日本血吸虫重组多表位抗原及其表达、纯化方法与应用 |
CN103191420A (zh) * | 2013-04-01 | 2013-07-10 | 南通大学 | 周期型马来丝虫复合多价dna疫苗的制备方法 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PT2640417T (pt) * | 2010-11-15 | 2020-06-25 | The Board Of Trustees Of The Univ Of Illionis | Vacina polivalente para filariose |
-
2014
- 2014-11-05 CN CN201610826365.9A patent/CN106344914B/zh not_active Expired - Fee Related
- 2014-11-05 CN CN201610824574.XA patent/CN106399345B/zh not_active Expired - Fee Related
- 2014-11-05 CN CN201610826363.XA patent/CN106399346B/zh active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101624422A (zh) * | 2008-07-09 | 2010-01-13 | 中国农业科学院上海兽医研究所 | 日本血吸虫重组多表位抗原及其表达、纯化方法与应用 |
CN103191420A (zh) * | 2013-04-01 | 2013-07-10 | 南通大学 | 周期型马来丝虫复合多价dna疫苗的制备方法 |
Non-Patent Citations (2)
Title |
---|
SATISH VEDI等: "Vaccination with 73 kDa recombinant heavy chain myosin generates high level of protection against Brugia malayi challenge in jird and mastomys models", 《VACCINE》 * |
谢东方等: "马来丝虫肌球蛋白基因序列及编码产物预测", 《中国公共卫生》 * |
Also Published As
Publication number | Publication date |
---|---|
CN106344914B (zh) | 2019-05-10 |
CN106399345A (zh) | 2017-02-15 |
CN104399069A (zh) | 2015-03-11 |
CN106344914A (zh) | 2017-01-25 |
CN106399346B (zh) | 2019-10-18 |
CN106399345B (zh) | 2019-09-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101624422A (zh) | 日本血吸虫重组多表位抗原及其表达、纯化方法与应用 | |
CN105131125B (zh) | 一种用于诱导外周血单个核细胞产生结核相关细胞因子的融合蛋白 | |
CN101921325B (zh) | 一种增加CD4+CD25+Foxp3+调节性T细胞的抗原及其应用 | |
CN107236039A (zh) | 重组Wzt蛋白兔血清多克隆抗体及其制备方法 | |
CN111840530A (zh) | 一种柔嫩艾美耳球虫重组多肽疫苗vnqs的制备及其在抗鸡球虫病中的应用方法 | |
CN106399346A (zh) | 周期型马来丝虫m29表位基因蛋白疫苗的用途 | |
CN114874995A (zh) | 猪瘟病毒2型Erns蛋白的单克隆抗体杂交瘤细胞株及应用 | |
dos Santos Alves et al. | Human coronavirus OC43-elicited CD4+ T cells protect against SARS-CoV-2 in HLA transgenic mice | |
CN109942693A (zh) | 一种微小隐孢子虫的ctl表位多肽及其应用和疫苗 | |
CN105461811B (zh) | 一种O型口蹄疫病毒多肽与SLA-2重链、轻链β2m复性结晶的方法 | |
CN104399069B (zh) | 周期型马来丝虫m29表位基因蛋白疫苗的制备方法 | |
CN103191420A (zh) | 周期型马来丝虫复合多价dna疫苗的制备方法 | |
CN104368014B (zh) | 周期型马来丝虫m29表位基因dna疫苗的制备方法 | |
Barfoed et al. | DNA immunization with 2C FMDV non-structural protein reveals the presence of an immunodominant CD8+, CTL epitope for Balb/c mice | |
CN113248578B (zh) | 新型冠状病毒(2019-nCoV)重组抗原及多克隆抗体 | |
CN104193827B (zh) | 一种丙型肝炎病毒第一高变区融合抗原及其应用 | |
CN114807059A (zh) | 新型pcv3病毒株及pcv3基因工程亚单位疫苗 | |
CN105504045B (zh) | 一种亚洲I型口蹄疫病毒多肽与SLA-2重链、轻链β2m复性、结晶的方法 | |
CN111190016A (zh) | 一种绵羊多胎性状的elisa快速检测方法和应用 | |
CN111850003A (zh) | 一种重组表达的多杀性巴氏杆菌硫胺素周质结合蛋白及应用 | |
CN105153290B (zh) | 日本血吸虫SjCTRL重组抗原蛋白及其制备方法和用途 | |
CN103834687A (zh) | 周期型马来丝虫复合多价蛋白疫苗的制备方法 | |
CN113564192B (zh) | 蜱传脑炎病毒衣壳蛋白c原核表达载体、重组菌株及其应用 | |
CN105906713B (zh) | 一种猪elf4蛋白卵黄抗体的制备方法 | |
CN113493498B (zh) | 2019-nCoV新冠病毒3CLpro蛋白的抗原表位多肽及其应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right |
Effective date of registration: 20210616 Address after: 226019 No.205, building 6, Nantong University, No.9, Siyuan Road, Nantong City, Jiangsu Province Patentee after: Center for technology transfer, Nantong University Address before: 226019 Jiangsu city of Nantong province sik Road No. 9 Patentee before: NANTONG University |
|
TR01 | Transfer of patent right | ||
EE01 | Entry into force of recordation of patent licensing contract |
Application publication date: 20170215 Assignee: Nantong Pharmaceutical Co.,Ltd. Assignor: Center for technology transfer, Nantong University Contract record no.: X2021980016479 Denomination of invention: APPLICATION OF PERIODIC BRUGIA MALAYI m29 epitope gene protein vaccine Granted publication date: 20191018 License type: Common License Record date: 20211228 |
|
EE01 | Entry into force of recordation of patent licensing contract | ||
EE01 | Entry into force of recordation of patent licensing contract |
Application publication date: 20170215 Assignee: Nantong Yifan Biotechnology Co.,Ltd. Assignor: Center for technology transfer, Nantong University Contract record no.: X2022320000352 Denomination of invention: Use of protein vaccine of M29 epitope gene of periodic Brugia malayi Granted publication date: 20191018 License type: Common License Record date: 20221210 |
|
EE01 | Entry into force of recordation of patent licensing contract | ||
CP03 | Change of name, title or address |
Address after: 226001 No.9, Siyuan Road, Chongchuan District, Nantong City, Jiangsu Province Patentee after: Nantong University Technology Transfer Center Co.,Ltd. Address before: 226019 No.205, building 6, Nantong University, No.9, Siyuan Road, Nantong City, Jiangsu Province Patentee before: Center for technology transfer, Nantong University |
|
CP03 | Change of name, title or address | ||
EE01 | Entry into force of recordation of patent licensing contract |
Application publication date: 20170215 Assignee: NANTONG HUIRAN BIOLOGICAL SCIENCE & TECHNOLOGY CO.,LTD. Assignor: Nantong University Technology Transfer Center Co.,Ltd. Contract record no.: X2023980053913 Denomination of invention: The use of the M29 epitope gene protein vaccine for periodic Malay filariasis Granted publication date: 20191018 License type: Common License Record date: 20231225 |
|
EE01 | Entry into force of recordation of patent licensing contract |